BEAM (Beam Therapeutics) 6-Month Price Index: 1.04 (As of Aug. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BEAM Beam Therapeutics Inc BEAM
70 GF Score
Price $30.19
GF Value $25.27
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Beam Therapeutics 6-Month Price Index?

Beam Therapeutics BEAM -2.71% 70 6-Month Price Index is 1.04 as of Aug. 27, 2026. GuruFocus rates BEAM with a GF Score™ of 70/100 and a GF Value™ of $25.27 (Modestly Overvalued). The stock has 4 warning signs investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-08-27), Beam Therapeutics's 6-Month Price Index is 1.04.

Beam Therapeutics  (NAS:BEAM) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Beam Therapeutics 6-Month Price Index Related Terms

BEAM vs KOD, TARS, VERA: 6-Month Price Index Comparison

For the Biotechnology subindustry, Beam Therapeutics's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BEAM
70GF Score
Beam Therapeutics Inc BEAM
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beam Therapeutics  (NAS:BEAM) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 1.04 mean?
Beam Therapeutics (BEAM) has a 6-Month Price Index of 1.04 as of Aug. 27, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Beam Therapeutics and its competitors.
Is Beam Therapeutics' 6-Month Price Index too high?
Beam Therapeutics' current 6-Month Price Index is 1.04. Overall, Beam Therapeutics has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' 6-Month Price Index compare to KOD and TARS?
Beam Therapeutics' 6-Month Price Index of 1.04 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Biotechnology company?
A good 6-Month Price Index depends on the Biotechnology industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Beam Therapeutics and its competitors. Beam Therapeutics's current 6-Month Price Index is 1.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (BEAM) is currently considered Modestly Overvalued. The stock's GF Value™ is $25.27, compared to a current price of $30.19 — trading 19.5% above its estimated fair value. The current 6-Month Price Index is 1.04. Beam Therapeutics' overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Beam Therapeutics (BEAM), the current 6-Month Price Index is 1.04 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beam Therapeutics (BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued. The current stock price of $30.19 is trading 19.5% above its estimated GF Value™ of $25.27. GuruFocus considers Beam Therapeutics to be Modestly Overvalued.

Key valuation signals for BEAM:

  • 6-Month Price Index: 1.04
  • GF Value™: $25.27 vs. price of $30.19 (19.5% above fair value)
  • GF Score™: 70/100 with 4 warning signs

No single metric tells the full story. See the BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beam Therapeutics Business Description

Other Exchanges BEAM:Mexico
Address 238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
70GF Score

Get the complete analysis for BEAM

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$30.19
Price
$25.27
GF Value